<ARTICLE> 5
<LEGEND>
This schedule contains second quarter and six months year-to-date summary
financial information extracted from Abbott Laboratories 1995 second quarter
10-Q and is qualified in its entirety by reference to such Form 10-Q filing.
</LEGEND>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               JUN-30-1995
<CASH>                                         254,395
<SECURITIES>                                    56,463
<RECEIVABLES>                                1,673,832
<ALLOWANCES>                                   155,059
<INVENTORY>                                  1,094,764
<CURRENT-ASSETS>                             4,040,131
<PP&E>                                       7,544,199
<DEPRECIATION>                               3,391,117
<TOTAL-ASSETS>                               8,990,323
<CURRENT-LIABILITIES>                        3,535,061
<BONDS>                                        435,730
<COMMON>                                       546,974
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   3,696,235
<TOTAL-LIABILITY-AND-EQUITY>                 8,990,323
<SALES>                                      5,024,707
<TOTAL-REVENUES>                             5,024,707
<CGS>                                        2,174,934
<TOTAL-COSTS>                                2,174,934
<OTHER-EXPENSES>                               534,535<F1>
<LOSS-PROVISION>                                41,871
<INTEREST-EXPENSE>                              31,804
<INCOME-PRETAX>                              1,193,311
<INCOME-TAX>                                   352,027
<INCOME-CONTINUING>                            841,284
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   841,284
<EPS-PRIMARY>                                     1.05
<EPS-DILUTED>                                     1.04
<FN>
<F1>OTHER EXPENSES CONSIST OF RESEARCH AND DEVELOPMENT EXPENSES